Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma

Arthritis Care and Research

Volumn 65, Issue 4, 2013, Pages 643-647

  Saadoun, D ^a   Pineton De Chambrun, M ^b   Hermine, O ^a   Karras, A ^c   Choquet, S ^b   Jego, P ^d   Decaux, O ^d,e   Cacoub, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; KIDNEY DISEASE; LUNG DISEASE; LUNG INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PLASMAPHERESIS; POLYNEUROPATHY; PURPURA; REFRACTORY PERIOD; REMISSION; SERUM SICKNESS; SINUSITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VASCULITIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CRYOGLOBULINEMIA; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE;

EID: 84875756281     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21856     Document Type: Article

References (15)

1. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287-308.
2. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, et al, and the Italian Group for the Study of Cryoglobulinaemias. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM 1995; 88: 115-26.
3. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365: 2067-77.
4. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F,. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818-26.
5. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
6. Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P,. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008; 67: 1431-6.
7. Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012; 119: 3184-5.
8. Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-9.
9. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009; 115: 5210-7.
10. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
11. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M,. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57: 775-88.
12. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon- alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.
13. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
14. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-53.
15. Sneller MC, Hu Z, Langford CA,. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 835-42.